A retrospective survival analysis of relapse rate in pediatric and adult autoimmune encephalitis (P4-5.003)

医学 美罗华 回顾性队列研究 自身免疫性脑炎 比例危险模型 儿科 内科学 危险系数 免疫学 自身抗体 抗体 淋巴瘤 置信区间
作者
Jennifer Yang,Emilie N. Liu,Linda Anh B. Nguyen,Anastasie M. Dunn‐Pirio,Jennifer Graves
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:100 (17_supplement_2)
标识
DOI:10.1212/wnl.0000000000202847
摘要

Objective:

To investigate relapse rate in pediatric and adult autoimmune encephalitis (AE)

Background:

Prior observational studies for AE have mostly focused on outcomes following acute immunotherapies. Varying relapse rates are reported among the different autoantibodies with limited evidence on long-term immunotherapy use after acute treatment and its associated clinical outcomes.

Design/Methods:

We conducted a retrospective study of consecutive patients meeting clinical criteria for AE evaluated at UC San Diego and Rady Children's Hospital from January 2007 to November 2021. Survival analysis and cox multivariable regression models were employed to evaluate relapse risk using rituximab exposure as a time-dependent variable.

Results:

A total of 35 pediatric (29 seropositive, 6 seronegative) and 75 adult (57 seropositive, 18 seronegative) patients were included in the study. The most common antibody subtype in both cohorts was anti-NMDA receptor (NMDAR). Relapses occurred in 31% of pediatric seropositive, 50% of pediatric seronegative, 38% of adult seropositive, and 27% of adult seronegative cases. Times to first relapse (TTFR) were 10.3 ± 7.4 months (pediatric seropositive), 6.9 ± 4.3 months (pediatric seronegative), 15.4 ± 29.3 months (adult seropositive), and 7.8 ± 6.5 months (adult seronegative). Combining pediatric and adult data, and adjusting for age and sex, rituximab use was associated with 74% lower hazard to relapse (HR 0.26, 95% CI 0.09 – 0.75, p= 0.01) for TTFR and the adjusted HR for rituximab use for recurring relapses was 0.36 (95% CI 0.15 – 0.87, p=0.03). The effect of rituximab was stronger for non-NMDA encephalitis than anti-NMDAR encephalitis (HR 0.39, 95% CI 0.16 – 0.96 vs HR 0.49, 95% CI 0.11 – 2.30).

Conclusions:

Relapses occur in approximately one-third of pediatric and adult patients with AE, although less frequent in anti-NMDARE. Our data demonstrate a substantial benefit of rituximab use for reducing relapse rate as acute or chronic immunotherapy. Disclosure: Dr. Yang has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurology Live. Dr. Yang has received research support from United Mitochondrial Disease Foundation. Miss Liu has received personal compensation for serving as an employee of SpineX Inc.. Dr. Nguyen has nothing to disclose. Dr. Dunn-Pirio has nothing to disclose. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Graves has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ACTN. The institution of Dr. Graves has received research support from Biogen. The institution of Dr. Graves has received research support from Octave. The institution of Dr. Graves has received research support from Sanofi. The institution of Dr. Graves has received research support from EMD Serono.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
orixero应助慧123采纳,获得10
2秒前
纯真忆安完成签到,获得积分20
2秒前
罗健完成签到 ,获得积分10
2秒前
sukiyaki发布了新的文献求助10
3秒前
XIXIw完成签到 ,获得积分10
3秒前
充电宝应助眉间一把刀采纳,获得10
3秒前
meetyou517应助标致的小霸王采纳,获得10
4秒前
5秒前
桐桐应助Yang采纳,获得10
5秒前
Squirrel发布了新的文献求助10
5秒前
glaze完成签到 ,获得积分10
5秒前
5秒前
淡淡铃铛发布了新的文献求助10
5秒前
JamesPei应助大昭采纳,获得10
6秒前
迅速的凡霜完成签到,获得积分20
6秒前
言无间发布了新的文献求助10
6秒前
Hello应助不停采纳,获得10
6秒前
6秒前
123456完成签到,获得积分20
6秒前
大模型应助XLH采纳,获得10
7秒前
传奇3应助科研通管家采纳,获得10
7秒前
乐乐应助科研通管家采纳,获得10
8秒前
搜集达人应助科研通管家采纳,获得10
8秒前
xuuu发布了新的文献求助10
8秒前
SHAO应助科研通管家采纳,获得10
8秒前
SHAO应助科研通管家采纳,获得10
8秒前
wanci应助科研通管家采纳,获得10
8秒前
情怀应助科研通管家采纳,获得30
8秒前
Orange应助科研通管家采纳,获得10
8秒前
8秒前
wanci应助科研通管家采纳,获得10
8秒前
汉堡包应助科研通管家采纳,获得10
9秒前
无花果应助科研通管家采纳,获得30
9秒前
思源应助科研通管家采纳,获得10
9秒前
英姑应助科研通管家采纳,获得10
9秒前
科目三应助科研通管家采纳,获得10
9秒前
在水一方应助科研通管家采纳,获得10
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961408
求助须知:如何正确求助?哪些是违规求助? 3507744
关于积分的说明 11137921
捐赠科研通 3240204
什么是DOI,文献DOI怎么找? 1790848
邀请新用户注册赠送积分活动 872587
科研通“疑难数据库(出版商)”最低求助积分说明 803288